PF-Atlas › Clinical Trials › NCT07679893
Phase 2 Clinical Trial of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
Nintedanib Dry Powder Inhalation · Phase 2
Registry ID
NCT07679893
Phase
Phase 2
Status
Recruiting
Drug / intervention
Nintedanib Dry Powder Inhalation
Sponsor
Mannkind Corporation
Start
2026-06-30
Enrollment
210
Locations
1
About this trial
This trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF). Participants are randomized to receive either 2 mg QID, 4 mg BID, or matching placebo for 12 weeks, followed by a 24-week open-label extension in which all participants receive active treatment. The primary focus is on safety-particularly bronchospasm events, lung function changes (FEV1, FEV1/FVC), and adverse event rates and assessing the effectiveness of nintedanib DPI in treating IPF.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT07679893 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.